(Q43077705)

13 November 2017

Curcumin inhibits hepatitis B virus via down-regulation of the metabolic coactivator PGC-1alpha (English)

1 reference

13 November 2017

0 references

1 reference

8

1 reference

13 November 2017

Maya Mouler Rechtman

1

1 reference

13 November 2017

Ofir Har-Noy

2

1 reference

13 November 2017

Iddo Bar-Yishay

3

1 reference

13 November 2017

Sigal Fishman

4

1 reference

13 November 2017

Yaarit Adamovich

5

1 reference

13 November 2017

Yosef Shaul

6

1 reference

13 November 2017

Zamir Halpern

7

1 reference

13 November 2017

language of work or name

English

0 references

publication date

29 April 2010

1 reference

13 November 2017

1 reference

13 November 2017

584

1 reference

13 November 2017

11

1 reference

13 November 2017

2485-2490

1 reference

Hepatitis B virus biology

13 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

Hepatitis B virus infection--natural history and clinical consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

Endpoints of therapy in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

PGC-1 coactivators: inducible regulators of energy metabolism in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

PGC-1alpha controls hepatitis B virus through nutritional signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

The metabolic activator FOXO1 binds hepatitis B virus DNA and activates its transcription.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

The "metabolovirus" model of hepatitis B virus suggests nutritional therapy as an effective anti-viral weapon

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

Biological properties of curcumin-cellular and molecular mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

Antiviral effect of Curcuma longa Linn extract against hepatitis B virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

Curcumin inhibits hepatitis C virus replication via suppressing the Akt-SREBP-1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an "in vitro" replicative system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

20S proteasomes and protein degradation "by default".

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

The nanny model for IDPs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

Inhibition of hepatitis B virus expression and replication by RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

Ubiquitin-independent p53 proteasomal degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

Systemic delivery of curcumin: 21st century solutions for an ancient conundrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2010.04.067

10.1016/J.FEBSLET.2010.04.067

21 January 2018

Identifiers

DOI

1 reference

13 November 2017

1 reference